Kostas Biliouris
Stock Analyst at BMO Capital
(0.96)
# 3,762
Out of 4,944 analysts
59
Total ratings
32.61%
Success rate
-20.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Market Perform | $25 → $50 | $20.40 | +145.10% | 8 | Jul 29, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | $15 → $4 | $2.97 | +34.68% | 1 | Jul 8, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $300 → $360 | $432.52 | -16.77% | 5 | Jun 24, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $30 → $8 | $3.09 | +158.90% | 2 | May 28, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $72 | $46.15 | +56.01% | 1 | Mar 12, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $50 | $12.24 | +308.50% | 1 | Mar 12, 2025 | |
| SLN Silence Therapeutics | Maintains: Outperform | $67 → $25 | $5.85 | +327.35% | 2 | Mar 4, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Market Perform | $60 → $45 | $43.10 | +4.41% | 2 | Feb 20, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $70 → $50 | $11.00 | +354.55% | 6 | Jan 10, 2025 | |
| DTIL Precision BioSciences | Upgrades: Outperform | $34 | $4.69 | +624.95% | 3 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $35 | $17.14 | +104.20% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $17 | $1.94 | +776.29% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $40 | $6.67 | +499.70% | 4 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $36.93 | +143.70% | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $18.93 | +533.91% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $17.52 | +225.34% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $50.38 | -26.56% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $58.30 | +71.53% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $3.81 | +398.69% | 1 | Oct 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $57.33 | +70.94% | 1 | Jun 17, 2022 |
Sarepta Therapeutics
Jul 29, 2025
Maintains: Market Perform
Price Target: $25 → $50
Current: $20.40
Upside: +145.10%
Jasper Therapeutics
Jul 8, 2025
Downgrades: Market Perform
Price Target: $15 → $4
Current: $2.97
Upside: +34.68%
Alnylam Pharmaceuticals
Jun 24, 2025
Maintains: Outperform
Price Target: $300 → $360
Current: $432.52
Upside: -16.77%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Outperform
Price Target: $30 → $8
Current: $3.09
Upside: +158.90%
Avidity Biosciences
Mar 12, 2025
Initiates: Outperform
Price Target: $72
Current: $46.15
Upside: +56.01%
Dyne Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $12.24
Upside: +308.50%
Silence Therapeutics
Mar 4, 2025
Maintains: Outperform
Price Target: $67 → $25
Current: $5.85
Upside: +327.35%
Ionis Pharmaceuticals
Feb 20, 2025
Maintains: Market Perform
Price Target: $60 → $45
Current: $43.10
Upside: +4.41%
Intellia Therapeutics
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $11.00
Upside: +354.55%
Precision BioSciences
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $4.69
Upside: +624.95%
Sep 16, 2024
Maintains: Outperform
Price Target: $20 → $35
Current: $17.14
Upside: +104.20%
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $1.94
Upside: +776.29%
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $6.67
Upside: +499.70%
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $36.93
Upside: +143.70%
May 15, 2024
Maintains: Outperform
Price Target: $120
Current: $18.93
Upside: +533.91%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $17.52
Upside: +225.34%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $50.38
Upside: -26.56%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $58.30
Upside: +71.53%
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $3.81
Upside: +398.69%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $57.33
Upside: +70.94%